Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 30,000 shares, a drop of 36.8% from the November 15th total of 47,500 shares. Based on an average daily trading volume, of 42,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.9% of the company’s stock are short sold.

Institutional Trading of Lakeshore Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of LSB. FMR LLC bought a new stake in shares of Lakeshore Biopharma during the 3rd quarter worth approximately $803,000. Hhlr Advisors LTD. acquired a new stake in Lakeshore Biopharma in the third quarter valued at $513,000. Finally, Barclays PLC bought a new position in shares of Lakeshore Biopharma in the 3rd quarter valued at about $169,000. Institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Stock Down 1.8 %

Lakeshore Biopharma stock traded down $0.04 during mid-day trading on Friday, reaching $2.50. The company’s stock had a trading volume of 4,609 shares, compared to its average volume of 14,336. The firm’s 50 day simple moving average is $2.86. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 0.17. Lakeshore Biopharma has a 12 month low of $1.88 and a 12 month high of $11.20.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.